CN102643275A - 一种达莎替尼n-6晶型新的制备方法 - Google Patents
一种达莎替尼n-6晶型新的制备方法 Download PDFInfo
- Publication number
- CN102643275A CN102643275A CN2011100411857A CN201110041185A CN102643275A CN 102643275 A CN102643275 A CN 102643275A CN 2011100411857 A CN2011100411857 A CN 2011100411857A CN 201110041185 A CN201110041185 A CN 201110041185A CN 102643275 A CN102643275 A CN 102643275A
- Authority
- CN
- China
- Prior art keywords
- dasatinib
- preparation
- cooled
- temperature
- crystal formation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110041185.7A CN102643275B (zh) | 2011-02-21 | 2011-02-21 | 一种达莎替尼n-6晶型新的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110041185.7A CN102643275B (zh) | 2011-02-21 | 2011-02-21 | 一种达莎替尼n-6晶型新的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102643275A true CN102643275A (zh) | 2012-08-22 |
CN102643275B CN102643275B (zh) | 2016-04-20 |
Family
ID=46656380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110041185.7A Active CN102643275B (zh) | 2011-02-21 | 2011-02-21 | 一种达莎替尼n-6晶型新的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102643275B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105030778A (zh) * | 2015-09-22 | 2015-11-11 | 青岛华之草医药科技有限公司 | 一种治疗血癌的药物达沙替尼组合物颗粒剂 |
CN105503854A (zh) * | 2015-12-31 | 2016-04-20 | 哈药集团技术中心 | 一种达沙替尼无水合物的新晶型物及其制备方法 |
CZ306598B6 (cs) * | 2012-12-06 | 2017-03-22 | Zentiva, K.S. | Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu |
CZ306732B6 (cs) * | 2013-12-19 | 2017-05-31 | Zentiva, K.S. | Způsob přípravy bezvodé polymorfní formy N-6 Dasatinibu |
CN108239086A (zh) * | 2016-12-27 | 2018-07-03 | 四川科伦药物研究院有限公司 | 一种达沙替尼n-6无水晶型的制备方法 |
WO2019209908A1 (en) | 2018-04-25 | 2019-10-31 | Johnson Matthey Public Limited Company | Crystalline forms of dasatinib |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060004067A1 (en) * | 2004-02-06 | 2006-01-05 | Bang-Chi Chen | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
WO2006052810A2 (en) * | 2004-11-04 | 2006-05-18 | Bristol-Myers Squibb Company | Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases |
WO2009053854A2 (en) * | 2007-10-23 | 2009-04-30 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
WO2010062715A2 (en) * | 2008-11-03 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
CN101891738A (zh) * | 2010-02-08 | 2010-11-24 | 南京卡文迪许生物工程技术有限公司 | 达沙替尼多晶型物及其制备方法和药用组合物 |
-
2011
- 2011-02-21 CN CN201110041185.7A patent/CN102643275B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060004067A1 (en) * | 2004-02-06 | 2006-01-05 | Bang-Chi Chen | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
WO2006052810A2 (en) * | 2004-11-04 | 2006-05-18 | Bristol-Myers Squibb Company | Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases |
WO2009053854A2 (en) * | 2007-10-23 | 2009-04-30 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
WO2010062715A2 (en) * | 2008-11-03 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
CN101891738A (zh) * | 2010-02-08 | 2010-11-24 | 南京卡文迪许生物工程技术有限公司 | 达沙替尼多晶型物及其制备方法和药用组合物 |
Non-Patent Citations (5)
Title |
---|
ALBAN J. ALLENTOFF,等: "Synthesis of 14C-labeled and 13C-,15N-labeled dasatinib and its piperazine N-dealkyl metabolite", 《J. LABEL COMPD. RADIOPHARM》, vol. 51, 8 January 2008 (2008-01-08), pages 41 - 47, XP002601139, DOI: doi:10.1002/jlcr.1469 * |
倪坤仪,等: "《药物分析学》", 31 March 2000, article "药物分析学", pages: 374-381 * |
朱强,等: "《化工单元过程及操作例题与习题》", 30 June 2005, article "化工单元过程及操作例题与习题", pages: 170-172 * |
李万才,等: "《生物分离技术》", 31 August 2009, article "生物分离技术", pages: 72-78 * |
杨高文,等: "《基础化学实验(有机化学部分)》", 31 December 2010, article "基础化学实验(有机化学部分)", pages: 259 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ306598B6 (cs) * | 2012-12-06 | 2017-03-22 | Zentiva, K.S. | Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu |
CZ306732B6 (cs) * | 2013-12-19 | 2017-05-31 | Zentiva, K.S. | Způsob přípravy bezvodé polymorfní formy N-6 Dasatinibu |
CN105030778A (zh) * | 2015-09-22 | 2015-11-11 | 青岛华之草医药科技有限公司 | 一种治疗血癌的药物达沙替尼组合物颗粒剂 |
CN105503854A (zh) * | 2015-12-31 | 2016-04-20 | 哈药集团技术中心 | 一种达沙替尼无水合物的新晶型物及其制备方法 |
CN108239086A (zh) * | 2016-12-27 | 2018-07-03 | 四川科伦药物研究院有限公司 | 一种达沙替尼n-6无水晶型的制备方法 |
CN108239086B (zh) * | 2016-12-27 | 2023-06-16 | 四川科伦药物研究院有限公司 | 一种达沙替尼n-6无水晶型的制备方法 |
WO2019209908A1 (en) | 2018-04-25 | 2019-10-31 | Johnson Matthey Public Limited Company | Crystalline forms of dasatinib |
US11440908B2 (en) | 2018-04-25 | 2022-09-13 | Johnson Matthey Public Limited Company | Crystalline forms of dasatinib |
Also Published As
Publication number | Publication date |
---|---|
CN102643275B (zh) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102643275A (zh) | 一种达莎替尼n-6晶型新的制备方法 | |
CN101973944B (zh) | 一种Gefitinib Form 1 晶型的制备方法 | |
CN102190649B (zh) | 一种制备α型甲磺酸伊马替尼的方法 | |
CN102030745B (zh) | Dasatinib溶剂合物及其制备方法 | |
CN102766097B (zh) | 一种依达拉奉a型晶体及其制备方法 | |
CN102311382B (zh) | 罗氟司特的晶态及其制备方法 | |
CN104364248B (zh) | 甲磺酸氟马替尼晶型及其制备方法和用途 | |
CN104910135A (zh) | 右旋雷贝拉唑钠新晶型的制备方法 | |
CN103319422B (zh) | 一种吉非替尼晶型及其制备方法 | |
CN103833640B (zh) | 一种依达拉奉晶体、其制备方法及其应用 | |
CN101768105A (zh) | 丁酸氯维地平的晶型 | |
CN104140414B (zh) | 阿昔替尼晶型的制备方法 | |
CN102838594B (zh) | 一种达沙替尼的制备及精制方法 | |
CN103059013A (zh) | 达沙替尼一水合物的新晶形及其制备方法 | |
CN104277005A (zh) | 一种吉非替尼Form 1晶型的制备方法 | |
CN105017142A (zh) | 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用 | |
CN109666019B (zh) | 一种氘代的氮唑醇类化合物及其制备方法和用途 | |
CN104829483B (zh) | 一种盐酸丙帕他莫a晶型的制备方法 | |
CN105801559B (zh) | 4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]氨基]苯甲酸乙酯的制备方法 | |
CN110642880A (zh) | 一种氮未取代吡唑和吲唑类硼酸的制备方法 | |
CN105461637A (zh) | 一种马西替坦晶型及其制备方法 | |
CN102731474A (zh) | 一种伊马替尼的制备方法 | |
CN104774150A (zh) | 一种双醋瑞因晶体及其制备方法 | |
CN103102316A (zh) | ZD1839Form 1晶型的制备方法 | |
CN112225732B (zh) | 一种盐酸哌罗匹隆水合物晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. Effective date: 20150604 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150604 Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Applicant after: Jiangsu Simcere Pharmaceutical Research Company Limited Applicant after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Applicant before: Jiangsu Simcere Pharmaceutical Research Company Limited |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160711 Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee before: Jiangsu Simcere Pharmaceutical Research Company Limited Patentee before: Jiangsu Simcere Pharmaceutical Co., Ltd. |